Associated Papers
Danicamtiv, a Selective Agonist of Cardiac Myosin, for Dilated Cardiomyopathy: A Phase 2 Open-Label Trial.
Lakdawala NK et al.
Journal of the American College of Cardiology, 2025
Exploring novel MYH7 gene variants using in silico analyses in Korean patients with cardiomyopathy.
Kim OH et al.
Bmc Medical Genomics, 2024
39237976 (PubMed )
Supplement: 12920_2024_2000_MOESM1_ESM.docx
Assessing Cardiac Contractility From Single Molecules to Whole Hearts.
Garg A et al.
Jacc. Basic to Translational Science, 2024
Clinical phenotypic characteristics in patients carrying MYH7-R143Q mutation with hypertrophic cardiomyopathy.
Zhang L et al.
Current Problems in Cardiology, 2024
Genetic Association of Beta-Myosin Heavy-Chain Gene (MYH7) with Cardiac Dysfunction.
Yousaf M et al.
Genes, 2022
Dilated cardiomyopathy myosin mutants have reduced force-generating capacity.
Ujfalusi Z et al.
The Journal of Biological Chemistry, 2018
Controlling load-dependent kinetics of β-cardiac myosin at the single-molecule level.
Liu C et al.
Nature Structural & Molecular Biology, 2018
How do mutations in contractile proteins cause the primary familial cardiomyopathies?
Marston SB
Journal of Cardiovascular Translational Research, 2011
Sarcomeric protein mutations in dilated cardiomyopathy.
Chang AN et al.
Heart Failure Reviews, 2005
Novel mutations in sarcomeric protein genes in dilated cardiomyopathy.
Daehmlow S et al.
Biochemical and Biophysical Research Communications, 2002
Select a paper to view details